ORIGINAL

The Spanish Burden of Disease 2010: Neurological, mental and substance use disorders

La carga de enfermedad en España 2010: Trastornos neurológicos mentales y relacionados con el consumo de sustancias

Elvira Lara. Parc Sanitari Sant Joan de Déu, Universitat de Barcelona, Sant Boi de
Llobregat, Barcelona, Spain.

Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental,
CIBERSAM, Madrid, Spain.

e.lara@pssjd.org

Noé Garin. Parc Sanitari Sant Joan de Déu, Universitat de Barcelona, Sant Boi de Llobregat,
Barcelona, Spain.

Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental,
CIBERSAM, Madrid, Spain.

noe.garin@pssjd.org

Alize J Ferrari. School of Population Health, University of Queensland, Herston,
Queensland, Australia; Queensland Centre for Mental Health Research, Wacol, Queensland,
Australia; University of Washington, Institute for Health Metrics and Evaluation, Seattle,
Washington, United States of America. alize_ferrari@qcmhr.uq.edu.au

Stefanos Tyrovolas. Parc Sanitari Sant Joan de Déu, Universitat de Barcelona, Sant Boi de
Llobregat, Barcelona, Spain.

Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental,
CIBERSAM, Madrid, Spain.

s.tyrovolas@pssjd.org

Beatriz Olaya. Parc Sanitari Sant Joan de Déu, Universitat de Barcelona, Sant Boi de Llobregat, Barcelona, Spain.

Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Madrid, Spain.

beatriz.olaya@pssjd.org

Lidia Sànchez-Riera. Institut d'Investigació Biomèdica de Bellvitge, Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain. 37416lsr@comb.cat

Harvey A Whiteford. School of Population Health, University of Queensland, Herston, Queensland, Australia. Queensland Centre for Mental Health Research, Wacol, Queensland, Australia; University of Washington, Institute for Health Metrics and Evaluation, Seattle, Washington, United States of America. h.whiteford@uq.edu.au

Josep Maria Haro. Parc Sanitari Sant Joan de Déu, Universitat de Barcelona, Sant Boi de Llobregat, Barcelona, Spain.

Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Madrid, Spain.

jmharo@pssjd.org

Address for correspondence

Dr. Josep Maria Haro

Email: jmharo@pssjd.org

Parc Sanitari Sant Joan de Déu, Fundació Sant Joan de Déu, CIBERSAM,

Dr. Antoni Pujadas, 42, 08830 – Sant Boi de Llobregat, Barcelona, Spain.

ABSTRACT

Introduction: We used data from the Global Burden of Disease, Injuries, and Risk Factors Study 2010 to report on the burden of neuropsychiatric disorders in Spain.

Materials and methods: The summary measure of burden used in the study was the disability-adjusted life-year (DALY), which sums of the years of life lost due to premature mortality (YLLs) and the years lived with disability (YLDs). DALYs were adjusted for comorbidity and estimated with 95% uncertainty intervals.

Results: The burden of neuropsychiatric disorders accounted for 18.4% of total all-cause DALYs generated in Spain for 2010. Within this group, the top five leading causes of DALYs were: depressive disorders, Alzheimer's disease, migraine, substance-use disorders, and anxiety disorder, which accounted for 70.9% of all DALYs due to neuropsychiatric disorders. Neurological disorders represented 5.03% of total all cause YLLs, whereas mental and substance-use disorders accounted for 0.8%. Mental and substance-use disorders accounted for 22.4% of total YLDs, with depression being the most disabling disorder. Neurological disorders represented 8.3% of total YLDs.

Conclusions: Neuropsychiatric disorders were one of the leading causes of disability in 2010. This finding contributes to our understanding of the burden of neuropsychiatric disorders in the Spanish population and highlights the importance of prioritising neuropsychiatric disorders in the Spanish public health system.

Key words: Burden of disease, neurological disorders, mental disorders, substance use disorders, disability-adjusted life-years, Spain.

RESUMEN

Introducción: Se analizan los datos españoles relacionados con los trastornos neurológicos, mentales y por consumo de sustancias procedentes del estudio Global Burden of Diseases (GBD 2010), Injuries and Risk Factors.

Materiales y métodos: Se calcularon los años de vida ajustados por discapacidad (AVAD), que son el resultado de la combinación de los años de vida perdidos por mortalidad prematura (AVP) y los años vividos con discapacidad (AVD). Los AVAD se ajustaron por comorbilidad y se estimaron con intervalos de confianza del 95%.

Resultados: La carga de los trastornos neuropsiquiátricos supuso el 18,4% del total de AVAD generados en España en 2010. Dentro de este grupo, las cinco causas principales de AVAD fueron: depresión, enfermedad de Alzheimer, migrañas, trastornos por consumo de sustancias y trastornos de ansiedad, que representaron el 70,9% del total de los trastornos neuropsiquiátricos. Los trastornos neurológicos supusieron el 5,03% del total de AVP, mientras que los trastornos mentales y de consumo de sustancias representaron el 0,8%. Los trastornos mentales y de consumo de sustancias constituyeron el 22,4% del total de AVD, siendo la depresión la enfermedad más incapacitante. Por otra parte, los trastornos neurológicos sumaron el 8,3% del total de AVD.

Conclusiones: Los trastornos neuropsiquiátricos fueron en España una de las principales causas de discapacidad en 2010. Este estudio contribuye al entendimiento de la carga que suponen dichos trastornos en la población española y pone de manifiesto la necesidad de dar prioridad a los trastornos neuropsiquiátricos en la sanidad pública española.

Palabras clave: Carga de la enfermedad, enfermedades neurológicas, enfermedades mentales, enfermedades de consumo de sustancias, años de vida ajustados por discapacidad, España.

Introduction

The Global Burden of Disease, Injuries, and Risk Factors Study (the GBD study), led by Murray and Lopez, was initially conducted in 1990¹. This study was the first large-scale, systematic effort to provide a comparable assessment of health loss due to diseases and injuries at both global and regional levels. In the GBD framework, the summary measure of disease burden is the disability-adjusted life-year (DALYs), which sums years of life lost due to premature mortality (YLLs) and years lived with disability (YLDs) due to a particular

disease². One DALY represents the loss of one year of full health. By combining YLLs and YLDs, DALYs facilitated the comparison of the burden of diseases and injuries that cause early death as well as those that cause disability, an approach that was ground-breaking in that it was able for the first time to highlight neuropsychiatric disorders (a disease category including neurological, mental and substance-use disorders) as leading causes of disease burden.

Notable key findings emerging from the 1990 study were that neuropsychiatric disorders accounted for more than 25% of global YLDs with five of the top ten causes of disability included within the neuropsychiatric category (unipolar major depression, alcohol use, bipolar disorder, schizophrenia and obsessive-compulsive disorders). Depression was the leading cause of YLDs while dementia was associated with high rates of both YLDs and YLLs³⁻⁶.

Investigations of prevalence within Europe also highlight mental and neurological disorders as a highly impacting group of disorders^{7,8,9,10}. For instance, in Spain, data from the ESeMed study reported a lifetime prevalence of mental disorders of 19.5%⁷. According to the National Institute of Statistics¹¹, neurological disorders were the fourth leading cause of death in Spain for 2012. Murray and colleagues (1997) estimated that, in 2020, the overall proportion of neuropsychiatric disorders will be 14.7% worldwide⁴. Similarly, the World Health Organisation estimated an increase of 15%¹², although in both instances, estimates were derived using data projections from previous years.

In 2007, a new Global Burden of Disease study (GBD 2010) was carried out and published in late 2012. Remarkable improvements in methodology were introduced to overcome limitations from the previous 1990 study, such as the use of population-based surveys to calculate disability weights which had been previously derived from expert consensus and the estimation of 95% uncertainty around all burden estimates¹³. GBD 2010 also expanded on the

set of neuropsychiatric disorders investigated. New categories (e.g. pervasive developmental disorders, childhood behavioural disorders) were included and existing categories were expanded (e.g., unipolar depression was divided into major depressive disorder and dysthymia; drug use disorders were divided into cocaine, cannabis, opioid and amphetamine dependence). Changes in methodology between the 1990 GBD study and its most recent iteration (GBD 2010) have been summarised in greater detail elsewhere^{6,14,15}. As these changes in methodology invalidated any comparison of burden estimates between the two studies, GBD 2010 estimated burden for both 1990 and 2010 to facilitate the investigation of burden across time¹⁶.

GBD 2010 findings highlighted that nine of the top twenty causes of disability were included within the neuropsychiatric category (e.g. depression, anxiety disorders, migraine, drug use disorders). Shifts in population growth and ageing due to increases in life expectancy also meant that more of the world's population were living to the age when neuropsychiatric disorders are most prevalent^{14,17}. Although GBD 2010 global findings for neuropsychiatric disorders has been previously reported^{6,14}, it is also important to present on the trends in burden at a national level. Knowledge of differences in burden at the country level is needed for priority setting in national health agendas and the development of health policies that address age, sex and year specific trends in burden and their impact on national health systems.

In this paper, we aim to report on the burden of neuropsychiatric disorders in Spain, for 1990 and 2010. To the best of our knowledge, this is the first study reporting on the burden of neuropsychiatric disorders in Spain using data from the GBD 2010 study.

Materials and methods

The GBD 2010 study involved a comprehensive assessment of burden for 291 diseases and injuries, and 67 risk factors for 20 age groups in 187 countries distributed across 21 world regions^{2,13,14,15}. Burden was assessed in terms of YLLs, YLDs and DALYs. Information about GBD 2010 definitions and methods will be briefly summarised here as they have been described in detail elsewhere^{13,14,15}.

In this paper, Spanish outcomes with respect to neuropsychiatric disorders are presented. Neuropsychiatric disorders were made up of neurological, mental and substance-use disorders, defined using the Diagnostic and Statistical Manual of Mental Disorders¹⁸ and the International Classification of Diseases¹⁹. More specifically, neurological disorders included: Alzheimer's disease and others dementias, Parkinson's disease, epilepsy, multiple sclerosis, migraine, tension-type headache. Mental and substance-use disorders were made up of schizophrenia, alcohol, opioid, cocaine, amphetamine, and cannabis dependence, depressive disorders (major depressive disorder and dysthymia), bipolar disorder, anxiety disorders, eating disorders, pervasive developmental disorders (autism, asperger's syndrome), childhood behavioural disorders (attention-deficit hyperactivity disorder, conduct disorder), idiopathic intellectual disability; and for disorders for which there was insufficient data to be assessed individually, three residual groups of other neuropsychiatric disorders were included¹⁴.

Years lost due to premature mortality (YLLs)

YLLs were calculated by multiplying the number of deaths attributable to a given disease by the standard life expectancy at the age of death for the Spanish population. Data on standard life expectancy came from standard model life tables derived specifically for GBD 2010¹². Estimates of death came from comprehensive reviews of vital registrations, verbal autopsy, mortality surveillance databases, and other sources dating back to 1980, for each of the 187 countries included in GBD 2010. Deaths could only be attributed to neuropsychiatric

disorders when the disorder was considered as the direct cause of death following ICD-10 guidelines^{15,16,20}. Based on this, deaths and YLLs were presented specifically for schizophrenia, alcohol-use disorders, drug-use disorders, anorexia nervosa, Alzheimer's disease, Parkinson's disease, multiple sclerosis, epilepsy and the residual groups of other neuropsychiatric disorders.

Years lived with disability (YLDs)

Systematic reviews of the published and unpublished literature were conducted to determine the global prevalence, incidence, remission, and excess-mortality associated with each disorder¹⁶. The case definition for each disorder followed criteria proposed by the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)¹⁸ or the International Classification of diseases (ICD-10)¹⁹. Neuropsychiatric disorders were included in the study when there was sufficient epidemiological information to generate defensible nationally-representative epidemiological estimates by age, sex and year. Although data on the prevalence of neuropsychiatric disorders were available for many countries, they were typically incomplete (e.g. not stratified by age, sex or year) and there was very little available on the incidence, remission and excess-mortality of these disorders. For that reason, DisMod-MR (Disease Modelling Meta-Regression), a Bayesian meta-regression tool, was used to reproduce for each disorder, from the raw epidemiological data that were available, consistent estimates of prevalence, incidence, remission and excess-mortality for all age, sex, country, and year groups^{14,16}. Uncertainty intervals (UIs) were also propagated from the raw epidemiological estimates to the final modelled output²¹.

YLDs were computed as the prevalence of a given disorder multiplied by the average disability weight for that disorder. In GBD 2010 a total of 1,160 sequelae were included to capture the clinical outcomes associated with specific diseases and injuries, which were

finally mapped onto 220 different health states. Disability weights were calculated for each health state to measure the degree of associated disability¹⁴.

New disability weights were computed for GBD 2010 using data collected through face-to-face interviews (in Peru, Bangladesh, Indonesia and Tanzania), telephone interviews (in the USA) and open access internet surveys. These efforts aimed to quantify the severity of health losses sustained for 220 health states on a range from 0 to 1, where 0 represents "perfect health" and 1, health loss proportionate to death^{13,22,23}. As some neuropsychiatric disorders comprised of more than one health state, multiple disability weights were estimated. This was done to better accommodate for differences in disability within the course of the disorder. Where this was the case, survey data reporting on the distribution of these health states in the population were then used to proportionally aggregate individual disability weights into an average disability weight¹⁴.

Disability weights were also adjusted for comorbidity between diseases using micro-simulation methods¹⁴. Uncertainty was also propagated from the DisMod-MR prevalence output, disability weights and death statistics through to final burden estimates. This method has been described in more detail elsewhere^{6,14,15}.

Finally, disability-adjusted life years (DALYs) were expressed as the sum of YLLs and YLDs¹⁵.

Results

Disability-adjusted lived years (DALYs)

Absolute burden

Overall, the diseases and injuries included in GBD 2010 generated 110,269.4 hundred DALYs in Spain in 2010. Neuropsychiatric disorders were responsible for 18.4% of this burden with 7,372.4 hundred (95% UI 6,127.5-8,666.4) DALYs due to neurological disorders, and 12,917.2 hundred (95% UI 10,630.6-15,432.4) DALYs due to mental and substance-use disorders. Table 1 shows the number of DALYs in 1990 and 2010 in Spain due to each neuropsychiatric disorder. The proportion of DALYs attributable to mental and substance-use disorders were almost double that of neurological disorders (11.7% vs. 6.7% respectively).

Between 1990 and 2010 absolute DALY values increased from 4.3% to 6.7% for neurological disorders and from 10% to 11.7% of total DALYs for mental and substance-use disorders. Within neuropsychiatric disorders, the top five leading causes of DALYs in 2010 were: depressive disorders, Alzheimer's disease, migraine, substance-use disorders, and anxiety disorders, accounting for 70.9% of all neuropsychiatric disorders. These DALY findings for 2010 are similar to those obtained in 1990 except for Alzheimer's disease (Table 1).

Sex and age trends

Regarding gender differences, DALYs for Alzheimer's disease, migraine, depressive disorders, anxiety disorders and eating disorders were highest in females. In comparison, DALYs for substance-use disorders, pervasive developmental disorders and childhood behavioural disorders were highest in males. (Table 1)

Overall, males accounted for 45.5% of total DALYs for neuropsychiatric disorders while females accounted for 54.5%. Figure 1a shows the distribution of DALYs due to mental and substance-use disorders (as a group) by age and sex. DALYs peaked between 25 to 44 years, accounting for 44.7% of DALYs. Up to 44 years, males explained a higher proportion of DALYs in mental and substance-use disorders whereas from 44 years old onwards, this effect

was reversed with females explaining a higher proportion of DALYs. Figure 1b shows the distribution of DALYs due to neurological disorders (as a group) by age and sex. DALYs increased substantially through life due to the contribution of disorders such as dementia that are more prevalent in the elderly. There was also a higher proportion of DALYs among females compared to males, especially in the elderly.

Figure 2a illustrates the distribution of DALYs attributable to each mental and substance-use disorder by age. Depressive disorders explained the highest proportion of DALYs throughout the entire life span representing 26% of all DALYs. The burden associated with substance-use disorders increased during adolescence, with a peak between 20-34 years. A similar course to that in drug-use disorders has been observed in alcohol-use disorders, accounting for 20.5% of burden among the youngest individuals (aged 15-29) and 58% for adults (aged 30-55), with a decrease over the years.

Less common mental disorders, such as bipolar disorder or schizophrenia, had a later onset although they tended to be more chronic. These accounted for the greatest proportion of burden from 25 to 55 years. DALYs due to other disorders such as eating disorders, anxiety disorders and childhood behavioural disorders were highest in childhood and adolescence, and in the case of anxiety disorders, the burden remained steady at all ages.

Figure 2b illustrates the distribution of DALYs due to neurological disorder by age, which shows a different pattern compared with that of mental and substance-use disorders. The distribution of DALYs was skewed to the right (i.e., a higher number of DALYs in older age groups), with Alzheimer's disease making the largest contribution to the burden (47.7%) of all neurological disorders. Migraine was the second leading cause of DALYs for neurological disorders (29%) and was highest amongst those aged 30-50 years. The burden of epilepsy

began in childhood, increased in adulthood and remained steady in the elderly. DALYs due to Parkinson's disease was also highest in the elderly.

Burden ranking

Figure 3 summarises the top 26 leading causes of DALYs in Spain, in 1990 and 2010. This was derived using burden rankings produced by GBD 2010¹⁵. Ischaemic heart disease maintained its position as the primary cause of DALYs in both 1990 and 2010 although, a number of neuropsychiatric disorders moved up in terms of ranking between 1990 and 2010. Four of the top twenty causes of DALYs in 2010 were neuropsychiatric disorders (i.e., depressive disorders, Alzheimer's disease, drug-use disorders, and migraine). In 1990, depressive disorders were ranked as the sixth leading cause of DALYs but reached fourth position in 2010, representing an increase of 35%. The most remarkable change was observed in Alzheimer's disease, with an increase of 145%, moving from eighteenth position in 1990 to eighth in 2010. Migraine and substance-use disorders were in the same position in 1990 and 2010, however, both saw an increase in terms of absolute of DALYs between the two time points (11% for substance-use disorders and 13% for migraine).

Years lived with disability (YLDs)

Table 2 shows YLDs and YLLs due to neuropsychiatric disorders in Spain, in 1990 and 2010. Overall, the diseases and injuries included in GBD 2010 generated 55,706.6 hundred YLDs. Mental and substance-use disorders made an important contribution, accounting for 22.4% of all YLDs in 2010. Depression was found to be the most disabling disease (5,308.1 hundred, 95% UI 3,910.9-7,025.8), accounting for 42.6% of mental and substance-use disorders. The burden attributable to depression in 1990 was lower (39.4%). Drug-use disorders and anxiety disorders accounted for 14.3% and 10.7% of mental and substance-use disorder YLDs

respectively. The leading causes of YLDs among neurological disorders were migraine and Alzheimer's disease, representing more than 80% of YLDs for neurological disorders. Compared with 1990, Alzheimer's disease increased its contribution to YLDs from 25.2% to 35.5%.

Years lost due to premature mortality (YLLs)

Overall, the diseases and injuries included in GBD 2010 generated 54,562.8 hundred YLLs in 2010. Neurological disorders accounted for 2,744.5 hundred (95% UI 2,092.35-3,423.72) YLLs, equivalent to 5.03% of total YLLs. Within this group, Alzheimer's disease was the main cause of mortality, accounting for 58.7% of YLLs for neurological disorders. Mental and substance-use disorders accounted for 453.07 hundred (95% UI 323.04-797.96) YLLs, equivalent to 0.8% of total YLLs. Within this group, substance-use disorders were the main cause of mortality accounting for 64.34% of YLLs for mental and substance-use disorders. (Table 2)

Discussion

In spite of the low contribution of neuropsychiatric disorders to global YLLs, this group of disorders was the most disabling, accounting for 30.7% of total YLDs in Spain in 2010. Overall, most neuropsychiatric disorders increased in burden between 1990 and 2010. This increase was driven by changes population growth and ageing and in some instances (e.g. for substance-use disorders) increases in the prevalence rate. Depressive disorders were the most disabling of the neuropsychiatric disorders due to the high prevalence and disability weight associated with major depressive disorder⁶. Nevertheless, it is important to note that, as illustrated by Whiteford and colleagues (2013), other neuropsychiatric disorders such as schizophrenia and Parkinson's disease were ranked with a high disability weight in GBD

2010 but accounted for a lower percentage of YLDs and DALYs because their prevalences were lower^{6,24}.

The burden of neuropsychiatric disorders varied across the lifespan. Burden was high in young adults and the elderly. The high proportion of burden due to neuropsychiatric disorders in young adults could be explained in some cases by an early onset of disorders associated with a high prevalence such as substance-use disorders, anxiety disorders and depressive disorders. The results also showed a high proportion of burden due to neurological disorders in the elderly. This was largely explained by the increase in the prevalence of highly disabling neurological disorders such as Alzheimer's disease or Parkinson's disease. As the population ages due to increases in life expectancy, it is expected that burden of diseases occurring in the elderly will also increase making neuropsychiatric disorders an important target for both the current and future health of the Spanish population²⁵.

Significant differences were found when comparing Spanish data with global results. In 2010, neuropsychiatric disorders accounted for 10.4% of all DALYs worldwide, and 15.4% in developed countries¹⁵, whereas in the Spanish population the figure was 18.4%. Although trends are similar in Spain and globally over the years, neuropsychiatric disorders make a larger contribution to disease burden in Spain.

Concerning the burden of disease in other European countries, we observed that, overall, the burden attributable to neuropsychiatric disorders was similar as well. All neuropsychiatric diseases included in the top 20 causes of DALYs increased their percentage contribution from 1990. Indeed, depression was the most disabling disorder among neuropsychiatric disorders in countries such as France, the United Kingdom, Germany and Italy, ranking between third and seventh position in terms of absolute DALYs. Other disorders, which were also among the 20 leading causes of DALYs in France, the United Kingdom, Germany and Italy, were

Alzheimer's disease, drug-use disorder, migraine, anxiety disorders or alcohol-use disorder, with varying percentages²⁶⁻²⁹.

Findings from GBD 2010 are in line with findings from previous epidemiological studies that have demonstrated the high impact of neuropsychiatric disorders in the population^{8,10}. For instance, the ESEMeD study reported a high prevalence of mental disorders in Spain, particularly depression⁷. Separate analyses of burden in Spain have also highlighted the impact of neuropsychiatric disorders, although there were differences in the methodology used to estimate burden. These studies also emphasised neuropsychiatric disorders as a leading contributor of total DALYs, especially for women and those ages between 15 and 30 years of age^{30,31}. Similarly, dementia was also highlighted as a major contributor of disease burden in the elderly³². Research focused on the Valencia and Andalusia regions of Spain obtained comparable results^{33,34}.

In spite of these findings, the direct and indirect costs of neuropsychiatric disorders are inadequately covered in most countries³⁴. The budget set for neuropsychiatric disorders in Spain represents less than 10% of public health expenditure³⁵ and not in line with our results which highlight neuropsychiatric disorders as a leading contributor to disability. Our findings underline the importance of prioritising neuropsychiatric disorders in the national health policies and allocating resources towards their prevention and management.

Limitations

Despite the progress made compared with previous GBD studies, we need to consider the limitations associated with GBD 2010 while interpreting findings. First, as the number of disorders included was limited, the burden of neuropsychiatric disorders may have been underestimated. Disorders were included if there was sufficient data to derive defensible

estimates of burden. As such, disorders such as personality disorders, somatoform disorders and substance-abuse were not included.

Second, neuropsychiatric disorders were defined according to DSM and ICD guidelines which may not capture all presentations of the disorders. However, this was necessary to facilitate the comparison of epidemiological data and burden estimates between settings. Future work on burden of disease will have to explore how recent changes to these guidelines (for instance, the changes proposed in the latest iteration of DSM) will impact on the estimated burden of neuropsychiatric disorders in Spain. Third, neuropsychiatric disorders contributed to a much smaller proportion of YLLs compared to YLDs. The ICD-10 guidelines used in GBD 2010's cause of death allocations can only attribute deaths to the direct (rather than the underlying) cause. As such, deaths due to neuropsychiatric were allocated to other causes in GBD 2010 (e.g. suicide related deaths due to having a mental disorder allocated to injuries) ^{9,22,36}.

Fourth, was the non-inclusion of social consequences in estimating disability weights. The impact of neuropsychiatric disorders on functioning and society at large, although well publicised was not considered^{37,38}. Finally, although 95% uncertainty intervals were presented for all high level findings in GBD 2010, given the lack of data available on the epidemiology of neuropsychiatric disorders, uncertainty intervals were often large and overlapping. This needs to be considered while interpreting findings. With ongoing epidemiological research and updates of GBD estimates, we aim to be able to reduce the unexplained sources of uncertainty around estimates of burden for neuropsychiatric disorders.

Conclusions

This study contributes to understanding of the burden of neuropsychiatric disorders in Spain and demonstrates that they should be considered an integral component of the public health system. Findings highlight the urgent need for health policy focusing on the development of effective and affordable approaches to reducing the existing burden of neuropsychiatric disorders in Spain and prevention programmes to reduce incident-cases of these disorders in the population. That said, more epidemiological research is needed for a better understanding of burden. Future studies should also consider the contribution of social and economic determinants to the burden of neuropsychiatric disorders.

Funding

This study has been supported by Bill & Melinda Gates Foundation. This study was done as part of GBD 2010.

Acknowledgments

We would like to acknowledge all members who have contributed to the Global Burden of Disease Study 2010 (GBD 2010). Specifically, we would like to thank the GBD 2010 Expert Groups on Neurological, Mental and substance use disorders and Illicit Drug. We would also like to express our sincere thanks to all Spanish participants in this study.

Bibliography

1. Das P, Samarasekera U. The story of GBD 2010: a “super-human” effort. *Lancet*. 2012;380(9859):2067–70.
2. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet*. 2012;380(9859):2224–60.
3. Murray CJ, Lopez a D. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. *Lancet*. 1997;349(9063):1436–42.
4. Murray CJL, Lopez a D. Alternative projections of mortality and disability by cause 1990- 2020: Global Burden of Disease Study. *Lancet*. 1997;349(9064):1498–1504.
5. López A, Murray C. The global burden of disease, 1990 – 2020. *Nat Med*. 1998;4(11):1241–3.
6. Whiteford H a, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine, HE, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. *Lancet*. 2013;382(9904):1575–86.
7. Haro JM, Palacín C, Vilagut G, Martínez M, Bernal M, Luque I, et al. Prevalencia de los trastornos mentales y factores asociados : resultados del estudio ESEMeD-España. *Med Clin (Barc)*. 2006;126(12):445–51.
8. Kessler R. Prevalence, Severity, and Unmet Need for Treatment of Mental Disorders in the World Health Organization World Mental Health Surveys. *Am Med Assoc*. 2004;291(21):2581–90.
9. Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. *Lancet*. 2007;370(9590):851–8.
10. King M, Nazareth I, Levy G, Walker C, Morris R, Weich S, et al. Prevalence of common mental disorders in general practice attendees across Europe. *Br J Psychiatry*. 2008;192(5):362–7.
11. Instituto Nacional de Estadística. Defunción según causa de muerte. 2012:1–14.
12. Reynolds, EH. Brain and mind : a challenge for WHO. *The Lancet*. 2003;361:3–4.

13. Murray CJL, Ezzati M, Flaxman AD, Lim S, Lozano R, Michaud C, et al. GBD 2010: design, definitions, and metrics. *Lancet*. 2012;380(9859):2063–6.
14. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet*. 2012;380(9859):2163–96.
15. Murray CJL, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet*. 2012;380(9859):2197–223.
16. Whiteford H a, Ferrari AJ, Baxter AJ, Charlson FJ, Degenhardt L. How did we arrive at burden of disease estimates for mental and illicit drug use disorders in the Global Burden of Disease Study 2010. *Curr Opin Psychiatry*. 2013;26(4):376–83.
17. Horton R. GBD 2010: understanding disease, injury, and risk. *Lancet*. 2012;380(9859):2053–4.
18. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-IV-TR), 4th text revision edn. Washington, DC: American Psychiatric Association; 2000.
19. WHO. The ICD-10 classification of mental and behavioural disorders: diagnostic criteria for research. Geneva: World Health Organization; 1993.
20. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet*. 2012;380(9859):2095–128.
21. Murray CJ, Richards M a, Newton JN, Fenton KA, Anderson HR, Atkinson C, et al. UK health performance: findings of the Global Burden of Disease Study 2010. *Lancet*. 2013;381(9871):997–1020.
22. Salomon J a, Vos T, Hogan DR, Gagnon M, Naghavi M, Mokdad A, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. *Lancet*. 2012;380(9859):2129–43.
23. Murray CJL, Acharya AK. Understanding DALYs. *J Health Econ*. 1997;16(6):703–30.
24. Rössler W, Salize HJ, van Os J, Riecher-Rössler A. Size of burden of schizophrenia and psychotic disorders. *Eur Neuropsychopharmacol*. 2005;15(4):399–409.
25. Salomon J a, Wang H, Freeman MK, Vos T, Flaxman AD, Lopez AD, et al. Healthy life expectancy for 187 countries, 1990-2010: a systematic analysis for the Global Burden Disease Study 2010. *Lancet*. 2012;380:2144–62.

26. Institute for Health Metrics and Evaluation. GBD profile: France. [consulted on 20/02/2014]. Available at: http://www.healthdata.org/sites/default/files/files/country_profiles/GBD/ihme_gbd_country_report_france.pdf
27. Institute for Health Metrics and Evaluation. GBD profile: United Kingdom. [consulted on 20/02/2014]. Available at: http://www.healthdata.org/sites/default/files/files/country_profiles/GBD/ihme_gbd_country_report_united_kingdom.pdf
28. Institute for Health Metrics and Evaluation. GBD profile: Germany. [consulted on 20/02/2014]. Available at: http://www.healthdata.org/sites/default/files/files/country_profiles/GBD/ihme_gbd_country_report_germany.pdf
29. Institute for Health Metrics and Evaluation. GBD profile: Italy. [consulted on 20/02/2014]. Available at: http://www.healthdata.org/sites/default/files/files/country_profiles/GBD/ihme_gbd_country_report_italy.pdf
30. Genova-Maleras R, Alvarez-Martin E, Morant-Ginestar C, de Larrea-Baz NF, Catala-Lopez F. Measuring the burden of disease and injury in Spain using disability- adjusted life years. *Public Health*. 2012;126(12):1024–31.
31. Catalá-López F, Gènova-Maleras R, Álvarez-Martín E. Carga de enfermedad en adolescentes y jóvenes en España. *Rev Psiquiatr Salud Ment (Barc)*. 2013;6(2):80-5.
32. Gènova-Maleras R, Álvarez-Martín E, Catalá-López F, Fernández de Larrea-Baz N, Morant-Ginestar C. Burden of disease in the elderly population in Spain. *Gac Sanit*. 2011;25 Suppl 2:47–50.
33. Catalá-López F, Gènova-Maleras R, Ridao M, et al. Burden of disease assessment with summary measures of population health for the Region of Valencia, Spain: a population-based study. *Med Clin (Barc)*. 2012;140(8):343–50.
34. Junta de Andalucía, Consejería de Salud. La carga de enfermedad en Andalucía en el año; 2008:1–9.
35. Olesen J, Gustavsson a, Svensson M, Wittchen H-U, Jönsson B. The economic cost of brain disorders in Europe. *Eur J Neurol*. 2012;19(1):155–62.
36. McDaid D, Knapp M, Curran C and MHEEN Group. Financing Arrangements for Mental Health in Western Europe. Mental Health Economics European Network. Phase 1 Final Report to the European Commission. Luxembourg: European Commission; 2004.
37. Rehm J, Mathers C, Popova S, Thavorncharoensap M, Teerawattananon Y, Patra J. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. *Lancet*. 2009;373(9682):2223–33.

38. Marmot M. Public Health Social determinants of health inequalities. *Lancet*. 2005;365:1099–1104.
39. Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E, et al. Cost of disorders of the brain in Europe 2010. *Eur Neuropsychopharmacol*. 2011;21(10):718–79.

Table 1. Comparison of DALYs due to neurological, mental and substance-use disorders in Spain, for 1990 and 2010 (In hundreds with 95% uncertainty)

	DALYs 1990 (both sexes)	DALYs 1990 (males)	DALYs 1990 (females)	DALYs 2010 (both sexes)	DALYs 2010 (males)	DALYs 2010 (females)
Total Mental and substance-use disorders	10,528.7 (8,600.5 – 12,716.4)	5,286.5 (4,215.1 – 6,532.2)	5,242.1 (4,162.8 – 6,510.9)	12,917.2 (10,630.6 – 15,432.4)	6,270.5 (5,059.6 – 7,675.9)	6,646.7 (5,365.6 – 8,124.2)
Schizophrenia	781.6 (453.6 – 1,153.9)	434.5 (232.9 – 701)	347.1 (183.8 – 550.9)	1,074.7 (606.8 – 1,614.1)	609 (318.8 – 973.4)	465.7 (242.7 – 751.9)
Alcohol use disorders	797 (482.4 – 1,257.7)	669.5 (381.2 – 1,105.8)	127.5 (62.4 – 222.5)	882.1 (514.8 – 1,385.4)	729.1 (393.2 – 1,209.2)	152.9 (83.8 – 266.8)
Drug use disorders	1,873.5 (1,391 – 2,416.5)	1,344.9 (980.4 – 1,765.8)	528.5 (373.7 – 717)	2,076 (1,536.1 – 2,677.5)	1,512.9 (1,105.8 – 1,992.3)	563.1 (400.2 – 736)
Depressive disorders	4,011.1 (2,829.7 – 5,395.6)	1,498.2 (1,041.1 – 2,109)	2,512.9 (1742.4 – 3,477)	5,308.1 (3,910.9 – 7,025.8)	2,008.6 (1,383.6 – 2,801.7)	3,299.5 (2,281.9 – 4,593.7)
Bipolar disorder	696.1 (425.1 – 1051)	315.1 (189 – 493.1)	381.1 (224.2 – 585.6)	835.3 (510.6 – 1251.2)	388.7 (228.8 – 606.5)	446.6 (260.7 – 676.9)
Anxiety disorders	1,213.6 (826.9 – 1,673.9)	413.8 (281.2 – 584.6)	799.8 (534.5 – 1,112.3)	1,331.1 (906.8 – 1,856.4)	429.2 (293.1 – 599.2)	901.9 (603.8 – 1,287.1)
Eating disorders	298.7 (174.6 – 479.3)	0.9 (0.5 – 2.3)	297.8 (173.1 – 477.9)	574.6 (339.7 – 929.5)	1.8 (0.6 – 2.8)	572.8 (337.7 – 927.5)
Pervasive developmental disorder	399.8 (269.4 – 578.2)	308 (203.2 – 448.9)	91.8 (59.6 – 132.8)	452.2 (302.8 – 648.9)	350.6 (233.1 – 515)	101.6 (67.8 – 144.9)
Childhood behavioural disorders	291.8 (171.3 – 450.9)	210.9 (122.4 – 337.6)	80.9 (46.6 – 123.7)	209.7 (120.2 – 323.4)	151.1 (84.6 – 239.8)	58.6 (34.9 – 92.4)
Idiopathic intellectual disability	92 (53.5 – 142.5)	56.5 (29.3 – 92.3)	35.6 (14.8 – 62.6)	74.1 (38 – 123.4)	43.3 (19.7 – 76.2)	30.8 (11 – 56.9)
Other mental disorders	73.4 (44.8 – 112.2)	34.2 (20.7 – 52.8)	39.2 (23.7 – 61.1)	99.2 (60.1 – 152.2)	46.3 (28.4 – 72)	52.9 (31.8 – 79.8)
Total Neurological disorders	4,581 (3,789.1 – 5,481.9)	1,829.6 (1,507.3 – 2,181.2)	2,751.4 (2,213.9 – 3,415.1)	7,372.4 (6,127.5 – 8,666.4)	2,971.3 (2,494.2 – 3,488.6)	4,401 (3,501.6 – 5,392.3)
Alzheimer's disease and other dementias	1,433.9 (1,138.4 – 1,754.3)	512.7 (398 – 627.6)	921.3 (703.9 – 1,185.4)	3,518 (2707.8 – 4,334.5)	1,313.6 (1,024.3 – 1,713.5)	2,204.3 (1,509.1 – 2,872.4)
Parkinson's disease	230.4 (180.8 – 300.8)	117.2 (85.2 – 173)	113.2 (83.5 – 154.8)	390 (290.8 – 496.1)	204.6 (139.3 – 280.4)	185.5 (122.5 – 252.3)
Epilepsy	399.4 (320.1 – 491.9)	216.2 (170.1 – 271.4)	183.1 (143 – 233.3)	432.1 (343 – 538.1)	230.4 (179.2 – 290.8)	201.7 (150.3 – 261.1)
Multiple sclerosis	82.1 (67.6 – 98.9)	33.1 (26.4 – 40.2)	49.1 (37.6 – 62.6)	109 (86.3 – 133.8)	40.8 (30.2 – 51.6)	68.2 (51 – 87.1)
Migraine	1,893.5 (1198.1 – 2731.1)	668.8 (404.9 – 988.4)	1,224.6 (751.6 – 1,839.2)	2,146 (1339.7 – 3101.9)	775.1 (480.7 – 1,197.1)	1,370.9 (789.8 – 2,077.9)
Tension-type headache	117.1 (65.8 – 188)	51.7 (28.8 – 85.6)	65.4 (35.3 – 106.9)	144.1 (82.7 – 233.9)	65.4 (37 – 108.5)	78.7 (43.5 – 133.5)
Other neurological disorders	424.5 (336.1 – 567.1)	229.8 (165.9 – 343.2)	194.7 (134.9 – 283)	633.1 (480.2 – 802.4)	341.4 (238.1 – 478.1)	291.7 (187.4 – 396)
All causes	104,615.9	57,820.0	46,795.8	110,269.4	58,722.5	51,546.9

Table 2. Comparison of YLLs and YLDs for neurological, mental and substance-use disorders in Spain for 1990 and 2010 (in hundreds, with 95% uncertainty)

	1990 YLDs	2010 YLDs	1990 YLLs	2010 YLLs
Total mental and substance-use disorders	10,177.2 (8,247.3 – 12,325.7)	12,464.1 (10,170.8 – 15,032.3)	351.53 (189.14 – 475.48)	453.07 (323.04 - 797.96)
Schizophrenia	771.1 (443.1 – 1,144.3)	1,052.2 (583.9 – 1,591.4)	10.56 (8.55 – 14.76)	22.53 (12.28 - 29.9)
Alcohol use disorders	691 (381.2 - 1156.4)	757.1 (401.2 – 1,235.8)	105.99 (55.37 – 188.36)	124.99 (77.51 - 260.19)
Drug use disorders	1,644.7 (1,176.5 – 2,156.1)	1,784.5 (1,277.6 – 2,334.5)	228.8 (84.18 – 318.42)	291.52 (165.61 - 588.06)
Depressive disorders	4,011.1 (2,829.7 – 5,395.6)	5,308.1 (3,910.9 – 7,025.8)	*	*
Bipolar disorder	696.1 (425.1 - 1051)	835.3 (510.6 – 1,251.2)	*	*
Anxiety disorders	1,213.6 (826.9 – 1,673.9)	1,331.1 (906.8 – 1,856.4)	*	*
Eating disorders	296.4 (171.5 - 476.8)	570.1 (334.2 - 924.9)	2.26 (1.5 – 4.39)	4.53 (2.04 - 6.56)
Pervasive developmental disorders	399.8 (269.4 - 578.2)	452.2 (302.8 - 648.9)	*	*
Childhood behavioural disorders	291.8 (171.3 - 450.9)	209.7 (120.2 - 323.4)	*	*
Idiopathic intellectual disability	92 (53.5 - 142.5)	74.1 (38 - 123.4)	*	*
Other mental disorders	69.5 (41 - 108.2)	89.7 (52 - 143.5)	3.92 (2.44 – 8.37)	9.5 (3.94 - 14.28)
Total Neurological disorders	3,407 (2,631.9 – 4,321.9)	4,627.9 (3,616.3 – 5,804.5)	1,174.02 (990.94 – 1,435.4)	2,744.5 (2,092.35 – 3,423.72)
Alzheimer's disease and other dementias	858.3 (612.7 – 1,136)	1,640.7 (1,185 – 2,196.8)	575.69 (422.65 – 784.89)	1,877.24 (1,253.43 – 2,491)
Parkinson's disease	71.8 (46 - 114.3)	115.7 (72.9 - 189)	158.63 (120.32 – 224.62)	274.27 (188.02 - 366.69)
Epilepsy	292 (215.3 - 381.1)	324 (242.9 - 425.2)	107.37 (86.05 – 140.31)	108.12 (77.25 - 127.15)
Multiple sclerosis	37.7 (26.5 - 51)	54.5 (37.3 - 74.1)	44.48 (35.82 – 56.74)	54.54 (39.84 - 70)
Migraine	1,893.5 (1,198.1 – 2,731.1)	2,146 (1,339.7 – 3,101.9)	*	*
Tension-type headache	117.1 (65.8 - 188)	144.1 (82.7 – 233.9)	*	*
Other neurological disorders	136.7 (102.7 - 176.2)	202.8 (153.7 - 261.7)	287.85 (199.41 – 430.24)	430.33 (278.35 - 593.29)
All causes	44,316.8	55,706.6	60,299.0	54,562.8